JP2024504257A5 - - Google Patents
Info
- Publication number
- JP2024504257A5 JP2024504257A5 JP2023537515A JP2023537515A JP2024504257A5 JP 2024504257 A5 JP2024504257 A5 JP 2024504257A5 JP 2023537515 A JP2023537515 A JP 2023537515A JP 2023537515 A JP2023537515 A JP 2023537515A JP 2024504257 A5 JP2024504257 A5 JP 2024504257A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- pharmaceutical composition
- compound according
- subject
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21382075.6 | 2021-01-29 | ||
| EP21382075.6A EP4036097A1 (en) | 2021-01-29 | 2021-01-29 | Ip4-4,6 substituted derivative compounds |
| PCT/EP2022/052164 WO2022162206A1 (en) | 2021-01-29 | 2022-01-31 | Ip4-4,6 substituted derivative compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024504257A JP2024504257A (ja) | 2024-01-31 |
| JP2024504257A5 true JP2024504257A5 (https=) | 2025-01-22 |
Family
ID=74732816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023537515A Pending JP2024504257A (ja) | 2021-01-29 | 2022-01-31 | Ｉｐ４－４，６置換誘導体化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240109924A1 (https=) |
| EP (2) | EP4036097A1 (https=) |
| JP (1) | JP2024504257A (https=) |
| KR (1) | KR20230132811A (https=) |
| CN (1) | CN116745304A (https=) |
| AR (1) | AR124717A1 (https=) |
| AU (1) | AU2022212601A1 (https=) |
| BR (1) | BR112023014549A2 (https=) |
| CA (1) | CA3202780A1 (https=) |
| IL (1) | IL303825A (https=) |
| MX (1) | MX2023008250A (https=) |
| TW (1) | TW202239414A (https=) |
| WO (1) | WO2022162206A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021380963A1 (en) * | 2020-11-20 | 2023-06-22 | ETH Zürich | Inositol hexakisphosphate analogues for treatment of calcification associated kidney diseases |
| AU2023313374A1 (en) * | 2022-07-29 | 2025-02-13 | Vifor (International) Ltd. | Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873355A (en) * | 1987-05-29 | 1989-10-10 | E. I. Du Pont De Nemours And Company | Process for regioselectively preparing phosphorylated inositols and other cyclitols |
| US4755612A (en) * | 1987-07-20 | 1988-07-05 | Merck & Co., Inc. | Intermediate compounds resulting from method for forming a dihydrogen-phosphate inositol |
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| EP0431197A4 (en) * | 1989-06-28 | 1991-12-04 | Mitsui Toatsu Chemicals Inc. | Myoinositol derivative and method of production thereof, and phosphorylating agent and its use |
| ES2124303T3 (es) | 1992-03-25 | 1999-02-01 | Depomed Inc | Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa. |
| US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| US5834436A (en) * | 1993-04-09 | 1998-11-10 | The Regents Of The University Of California | Membrane-permeant second messengers |
| AU3290397A (en) | 1996-06-10 | 1998-01-07 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| WO1998055107A1 (en) | 1997-06-06 | 1998-12-10 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| HK1050135A1 (zh) | 1999-11-02 | 2003-06-13 | Depomed, Inc. | 用於促进将药物给予胃的饭後模式药理学诱导 |
| DE60123384T2 (de) | 2000-02-04 | 2007-08-02 | DepoMed, Inc., Menlo Park | Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert |
| US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
| US6451808B1 (en) | 2000-10-17 | 2002-09-17 | Depomed, Inc. | Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists |
| MXPA03011096A (es) | 2001-05-29 | 2004-12-06 | Depomed Dev Ltd | Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna. |
| US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| JP2005508358A (ja) | 2001-10-25 | 2005-03-31 | デポメド・インコーポレイテッド | 胃滞留型ロサルタン投与量を用いる治療方法 |
| US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
| ES2232302B1 (es) * | 2003-11-07 | 2006-08-01 | Universitat De Les Illes Balears | Myo-inositol hexafosfato para uso topico. |
| ES2288126B2 (es) | 2006-06-01 | 2009-07-06 | Universitat De Les Illes Balears | Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis. |
| ES2332636B1 (es) | 2008-08-06 | 2011-02-10 | Universitat De Les Illes Balears | Composicion de liquido de dialisis. |
| EP2579036A1 (en) | 2011-10-06 | 2013-04-10 | Laboratorios Sanifit, S.L. | Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200 |
| JP6893037B2 (ja) | 2015-12-11 | 2021-06-23 | エーテーハー・チューリッヒＥＴＨ Ｚｕｒｉｃｈ | Ｃ．ｄｉｆｆｉｃｉｌｅ感染のための４，６−ジ−（Ｏ−チオホスフェート）−イノシトール−１，２，３，５−テトラ−Ｏ−スルフェート |
| DK3386548T3 (da) * | 2015-12-11 | 2021-05-25 | Eth Zuerich | Inositol-derivater til anvendelse i patologisk krystallisering |
| WO2019176693A1 (ja) * | 2018-03-15 | 2019-09-19 | 国立大学法人広島大学 | 骨外組織における骨形成関連因子又は石灰化関連因子の発現抑制剤 |
-
2021
- 2021-01-29 EP EP21382075.6A patent/EP4036097A1/en not_active Withdrawn
-
2022
- 2022-01-27 TW TW111103698A patent/TW202239414A/zh unknown
- 2022-01-28 AR ARP220100172A patent/AR124717A1/es unknown
- 2022-01-31 EP EP22703600.1A patent/EP4284809A1/en active Pending
- 2022-01-31 CA CA3202780A patent/CA3202780A1/en active Pending
- 2022-01-31 JP JP2023537515A patent/JP2024504257A/ja active Pending
- 2022-01-31 AU AU2022212601A patent/AU2022212601A1/en active Pending
- 2022-01-31 WO PCT/EP2022/052164 patent/WO2022162206A1/en not_active Ceased
- 2022-01-31 KR KR1020237027325A patent/KR20230132811A/ko active Pending
- 2022-01-31 BR BR112023014549A patent/BR112023014549A2/pt unknown
- 2022-01-31 US US18/274,805 patent/US20240109924A1/en active Pending
- 2022-01-31 MX MX2023008250A patent/MX2023008250A/es unknown
- 2022-01-31 CN CN202280012575.8A patent/CN116745304A/zh active Pending
- 2022-01-31 IL IL303825A patent/IL303825A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020189864A5 (https=) | ||
| JP7241856B2 (ja) | ビス第四級アンモニウム化合物及びその製造方法と使用 | |
| JP2024504257A5 (https=) | ||
| JP2022522694A5 (https=) | ||
| KR101986272B1 (ko) | 삼환식 화합물, 이를 포함하는 조성물 및 그의 용도 | |
| EA023500B1 (ru) | Соединения, композиции и способы их применения для коррекции уровня мочевой кислоты | |
| RU2011127079A (ru) | Комбинация производного циклоспорина и нуклеозидов для лечения инфекции вирусом гепатита с | |
| JP2014500295A5 (https=) | ||
| JP2007191486A5 (https=) | ||
| BRPI0817864A2 (pt) | uso de um composto derivado de ceramida | |
| RU2014143250A (ru) | Производные 7-оксо-тиазолопиридин карбоновой кислоты и их применение при лечении, облегчении или профилактике вирусного заболевания | |
| RU2007101653A (ru) | Производные 1-азабицикло[3.3.1]нонанов | |
| RU2014139169A (ru) | Парентеральные составы для введения макролидных антибиотиков | |
| JP2022537140A5 (https=) | ||
| BG99164A (bg) | Антиисхемично лекарствено средство | |
| JP2022541545A5 (https=) | ||
| JP2008521908A5 (https=) | ||
| JPH04505760A (ja) | Ａｚｔの副作用および毒性からの保護方法 | |
| RU2220965C2 (ru) | Сульфонамидозамещенные соединения и фармацевтический состав на их основе | |
| JPH1036365A5 (https=) | ||
| CN107428753A (zh) | 用于治疗原发性癌症和癌症转移的小分子 | |
| JPS6248678B2 (https=) | ||
| JPH0317094A (ja) | レベカマイシン類似体の安定な溶液およびその製造 | |
| JP2022536043A5 (https=) | ||
| US3701829A (en) | Treatment of parkinson's disease |